Marketing: Page 2
-
Lilly's case for Taltz helped by expanded approval
By prescription numbers, Taltz trails Novartis' rival drug Cosentyx. An approval for use in ankylosing spondylitis will go some ways to level the playing field.
By Ned Pagliarulo • Aug. 26, 2019 -
SponsoredToday's data linkage is tomorrow's privacy breach
Is your company at risk?
By Crossix Solutions • Aug. 22, 2019 -
Trump administration not giving up on plan to require prices in TV drug ads
Amgen, Merck and Eli Lilly successfully blocked the rule from taking effect in July, winning a district court decision that HHS is now appealing.
By Ned Pagliarulo • Aug. 21, 2019 -
NHS coverage opens up Hemlibra to thousands more patients
The decision could help Roche's hemophilia drug make headway in the European market, especially among patients without inhibitors.
By Jacob Bell • Aug. 21, 2019 -
Amgen biosimilar debut boosted by UnitedHealthcare coverage switch
Recently launched Mvasi and Kanjinti, copycat versions of Avastin and Herceptin respectively, will be preferred products for the insurer starting October 1.
By Ned Pagliarulo • UPDATED: Aug. 19, 2019 at 2:01 p.m. -
Nonprofit under pressure to make new TB drug affordable
Doctors Without Borders is calling on the TB Alliance to set a low price for the drug, and to put money from a sale of a regulatory fast pass toward patient access.
By Jacob Bell • Aug. 15, 2019 -
Gilead's Descovy set for PrEP approval, but not without data, access concerns
An expert panel recommended the FDA extend approval of Gilead's drug for preventive use, though advisers pushed for further study in cisgender women.
By Jacob Bell • Aug. 08, 2019 -
Regulators, Gilead at odds over HIV drug's use in women
An expert panel today will discuss Gilead's application for Descovy's use as a preventive treatment for HIV.
By Jacob Bell • Aug. 05, 2019 -
Congress is going after drug prices. Pharma CEOs aren't panicking, yet
A Senate Finance bill could emerge as the most palatable option for an industry seeking to limit losses in an election cycle already targeting pricing as an issue.
By Ned Pagliarulo • Aug. 02, 2019 -
White House backs importing drugs from abroad
The Trump administration's latest drug price plan features ideas Republicans traditionally oppose and breaks with past claims about the FDA's ability to safely oversee importation.
By Jonathan Gardner • July 31, 2019 -
SponsoredDoes your brand need behavioral science?
Does your brand need a behavioral science solution? Find the right solution to meet your needs.
By Meredith Terry, PhD Lead Behaviorist, Innovation and Practice MicroMass Communications, Inc. • July 31, 2019 -
Sales gap grows between rival Merck, Bristol cancer therapies
Keytruda posted $2.6 billion in sales during the second quarter, spurring Merck to substantially boost its revenue projections for the year.
By Ned Pagliarulo • July 30, 2019 -
FTC probing J&J on Remicade, as biosimilar market remains muted
The anti-inflammation drug has held onto its market share despite years of biosimilar competition. Now, the FTC wants to know how.
By Andrew Dunn • July 30, 2019 -
European regulators back Bayer, GW drugs, but with caveats
The CHMP recommended conditional approval of Vitrakvi while also advising Epidiolex be used as adjunctive therapy, an opinion one analyst described as "disappointing."
By Jacob Bell • July 26, 2019 -
FDA warns cannabis company for illegal marketing of CBD products
At issue are "unsubstantiated claims" made by Curaleaf about the health benefit of its cannabidiol products.
By Kristin Jensen • July 24, 2019 -
Advocacy group pledges six-figure ad buy to support Trump drug price plan
Patients for Affordable Drugs relaunched a campaign which supports the Trump administration's proposed International Pricing Index for certain drugs.
By Jonathan Gardner • July 17, 2019 -
SponsoredWeathering the privacy storm
How to stay above water in the changing digital marketing landscape.
-
Xarelto falls into the donut hole
A 19% decline from 2018 sales was a dark cloud in an otherwise mostly positive quarterly earnings for Johnson & Johnson.
By Jonathan Gardner • July 16, 2019 -
ICER unconvinced peanut allergy drugs are better than just avoiding the food
The influential cost watchdog group argues that treatments from DBV and Aimmune haven't shown long-term benefits — or, more broadly, quality-of-life improvements.
By Jacob Bell • July 11, 2019 -
Billion-dollar settlement gets Reckitt out of federal opioid probes
Company spinout Indivior, however, is still facing criminal charges related to marketing of Suboxone film, an opioid dependence treatment.
By Jonathan Gardner • July 11, 2019 -
New GSK data raises threat to Gilead's star HIV drug
Dovato, GSK's two-drug HIV treatment, maintained viral suppression about as well as three-drug regimens with a similar makeup to Gilead's Biktarvy.
By Jacob Bell • July 10, 2019 -
UK testing Netflix-style payments to boost antibiotics development
Officials hope the model will overcome some of the obstacles that have stifled the commercial prospects for new antibiotics.
By Jacob Bell • July 09, 2019 -
In win for pharma, Trump TV drug price rule struck down
The federal district court sided with drugmakers, which argued the government overstepped its authority in forcing price transparency in advertisements.
By Jonathan Gardner • July 09, 2019 -
BioMarin confirms timeline for hemophilia gene therapy, putting pressure on rivals
The biotech plans on submitting valrox to U.S. and European regulators in the fourth quarter, which could bring approval decisions by mid-2020.
By Jacob Bell • July 08, 2019 -
Zolgensma set a new drug pricing bar. Insurers show some signs of pushback
One month after approval, a handful of payers have adopted policies taking a more cautious stance than what the FDA set out in the gene therapy's label.
By Ned Pagliarulo • UPDATED: July 5, 2019 at 4:24 p.m.
Previous
